# Laurus Labs (NSE: LAURUSLABS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/LAURUSLABS · Pivot · prices to 21 Oct 2026

Laurus Labs (NSE: LAURUSLABS) closed at ₹2,026.10 on 21 Oct 2026. With a market capitalisation of ₹1,11,394 Cr, it ranks 89th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 124.8× trailing earnings, against a return on equity of 8.0% in FY25. Over the past year the share price has risen 135.1%. Its 52-week range is ₹902.35 (24 Oct 2025) to ₹2,089.00 (19 Oct 2026); the last close is 3.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,026 Cr (+29.1% year on year) and net profit ₹362 Cr (+124.7%), on a consolidated basis. Promoters held 27.47% of the company as of 30 Jun 2026; 2.69% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,026.10 |
| Market cap | ₹1,11,394 Cr |
| P/E (trailing) | 124.8 |
| ROE | 8.0% (FY25) |
| ROCE | 11.8% (FY25) |
| Debt to equity | 0.6 |
| 52-week high | ₹2,089.00 (19 Oct 2026) |
| 52-week low | ₹902.35 (24 Oct 2025) |
| 1-year return | +135.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹2,026 Cr | +29.1% | ₹362 Cr | +124.7% | ₹6.81 |
| Q4 FY26 | ₹1,812 Cr | +5.3% | ₹282 Cr | +20.5% | ₹5.17 |
| Q3 FY26 | ₹1,778 Cr | +25.7% | ₹253 Cr | +179.3% | ₹4.67 |
| Q2 FY26 | ₹1,653 Cr | +35.1% | ₹194 Cr | +993.4% | ₹3.61 |
| Q1 FY26 | ₹1,570 Cr | +31.4% | ₹161 Cr | +1,219.2% | ₹3.02 |
| Q4 FY25 | ₹1,720 Cr | +19.5% | ₹234 Cr | +210.5% | ₹4.34 |
| Q3 FY25 | ₹1,415 Cr | +18.4% | ₹91 Cr | +260.0% | ₹1.71 |
| Q2 FY25 | ₹1,224 Cr | −0.1% | ₹18 Cr | −54.9% | ₹0.37 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹5,554 Cr | ₹354 Cr |
| FY24 | ₹5,041 Cr | ₹168 Cr |
| FY23 | ₹6,041 Cr | ₹797 Cr |
| FY22 | ₹4,936 Cr | ₹832 Cr |
| FY21 | ₹4,814 Cr | ₹984 Cr |
| FY20 | ₹2,832 Cr | ₹255 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 27.47%
- Foreign institutions: 28.00%
- Domestic institutions: 13.74%
- Non-institutions: 30.78%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Zydus Lifesciences](https://app.pivotnow.in/stock/ZYDUSLIFE) | ₹1,111.50 | ₹1,10,873 Cr | 22.2 | — |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,695.00 | ₹1,10,642 Cr | 57 | — |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,324.00 | ₹1,06,959 Cr | 27.5 | — |
| [Dr. Reddy's Laboratories](https://app.pivotnow.in/stock/DRREDDY) | ₹1,241.20 | ₹1,03,600 Cr | — | — |
| [Aurobindo Pharma](https://app.pivotnow.in/stock/AUROPHARMA) | ₹1,617.00 | ₹93,039 Cr | 26.8 | — |
| [Mankind Pharma](https://app.pivotnow.in/stock/MANKIND) | ₹2,251.00 | ₹92,965 Cr | 48.7 | — |

## Questions and answers

### What is the share price of Laurus Labs today?

Laurus Labs (NSE: LAURUSLABS) last closed at ₹2,026.10 on 21 Oct 2026. Its 52-week high is ₹2,089.00 and its 52-week low is ₹902.35.

### What is the market cap of Laurus Labs?

Laurus Labs' market capitalisation is ₹1,11,394 Cr (₹1.11 lakh Cr) at the 19 Oct 2026 close, ranking 89th among the NSE companies Pivot tracks.

### What is the P/E ratio of Laurus Labs?

Laurus Labs trades at a trailing P/E of 124.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 27.5.

### What is the ROE and ROCE of Laurus Labs?

Return on equity was 8.0% in FY25 and return on capital employed was 11.8% in FY25 (consolidated figures).

### Is Laurus Labs a debt-free company?

No. Laurus Labs' debt-to-equity ratio was 0.6 in FY25, with total debt of ₹646 Cr.

### What were Laurus Labs' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Laurus Labs reported revenue of ₹2,026 Cr, +29.1% year on year, and net profit of ₹362 Cr, +124.7% year on year.

### How has Laurus Labs stock performed over the last year?

Laurus Labs' share price has risen 135.1% over the past year, +32.2% over three months and +5.3% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Laurus Labs?

As of 30 Jun 2026: promoters 27.47%, foreign institutions 28.00%, domestic institutions 13.74%, non-institutions 30.78%. 2.69% of promoter shares were pledged.

### Who are Laurus Labs' competitors?

The listed Pharma & Healthcare companies closest to Laurus Labs by market cap are Zydus Lifesciences, Apollo Hospitals Enterprise, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma and Mankind Pharma.

### Is Laurus Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Laurus Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LAURUSLABS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.